» Articles » PMID: 35660417

Reticular Pseudodrusen: The Third Macular Risk Feature for Progression to Late Age-Related Macular Degeneration: Age-Related Eye Disease Study 2 Report 30

Overview
Journal Ophthalmology
Publisher Elsevier
Specialty Ophthalmology
Date 2022 Jun 6
PMID 35660417
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: To analyze reticular pseudodrusen (RPD) as an independent risk factor for progression to late age-related macular degeneration (AMD), alongside traditional macular risk factors (soft drusen and pigmentary abnormalities) considered simultaneously.

Design: Post hoc analysis of 2 clinical trial cohorts: Age-Related Eye Disease Study (AREDS) and AREDS2.

Participants: Eyes with no late AMD at baseline in AREDS (6959 eyes, 3780 participants) and AREDS2 (3355 eyes, 2056 participants).

Methods: Color fundus photographs (CFPs) from annual visits were graded for soft drusen, pigmentary abnormalities, and late AMD. Presence of RPD was from grading of fundus autofluorescence images (AREDS2) and deep learning grading of CFPs (AREDS). Proportional hazards regression analyses were performed, considering AREDS AMD severity scales (modified simplified severity scale [person] and 9-step scale [eye]) and RPD presence simultaneously.

Main Outcome Measures: Progression to late AMD, geographic atrophy (GA), and neovascular AMD.

Results: In AREDS, for late AMD analyses by person, in a model considering the simplified severity scale simultaneously, RPD presence was associated with a higher risk of progression: hazard ratio (HR), 2.15 (95% confidence interval [CI], 1.75-2.64). However, the risk associated with RPD presence differed at different severity scale levels: HR, 3.23 (95% CI, 1.60-6.51), HR, 3.81 (95% CI, 2.38-6.10), HR, 2.28 (95% CI, 1.59-3.27), and HR, 1.64 (95% CI, 1.20-2.24), at levels 0-1, 2, 3, and 4, respectively. Considering the 9-step scale (by eye), RPD presence was associated with higher risk: HR, 2.54 (95% CI, 2.07-3.13). The HRs were 5.11 (95% CI, 3.93-6.66) at levels 1-6 and 1.78 (95% CI, 1.43-2.22) at levels 7 and 8. In AREDS2, by person, RPD presence was not associated with higher risk: HR, 1.18 (95% CI, 0.90-1.56); by eye, it was HR, 1.57 (95% CI, 1.31-1.89). In both cohorts, RPD presence carried a higher risk for GA than neovascular AMD.

Conclusions: Reticular pseudodrusen represent an important risk factor for progression to late AMD, particularly GA. However, the added risk varies markedly by severity level, with highly increased risk at lower/moderate levels and less increased risk at higher levels. Reticular pseudodrusen status should be included in updated AMD classification systems, risk calculators, and clinical trials.

Citing Articles

Antioxidants in Age-Related Macular Degeneration: Lights and Shadows.

Parmar U, Surico P, Mori T, Singh R, Cutrupi F, Premkishore P Antioxidants (Basel). 2025; 14(2).

PMID: 40002339 PMC: 11852319. DOI: 10.3390/antiox14020152.


Current advances in multimodal imaging in geographic atrophy secondary to age-related macular degeneration: A review.

Cohn A, Guymer R Taiwan J Ophthalmol. 2025; 14(4):464-472.

PMID: 39803396 PMC: 11717336. DOI: 10.4103/tjo.TJO-D-24-00065.


TEN-YEAR FOLLOW-UP OF FELLOW EYES IN PATIENTS WITH UNILATERAL NAIVE EXUDATIVE AGE-RELATED MACULAR DEGENERATION.

Pozzo Giuffrida F, Nassisi M, de Sanctis L, Milella P, Malerba A, Mapelli C Retina. 2024; 44(12):2049-2056.

PMID: 39172949 PMC: 11559965. DOI: 10.1097/IAE.0000000000004251.


Extent and Topography of Subretinal Drusenoid Deposits Associate With Rod-Mediated Vision in Aging and AMD: ALSTAR2 Baseline.

Goerdt L, Amjad M, Swain T, McGwin G, Clark M, Owsley C Invest Ophthalmol Vis Sci. 2024; 65(10):25.

PMID: 39163034 PMC: 11343004. DOI: 10.1167/iovs.65.10.25.


Reticular Pseudodrusen: Impact of Their Presence and Extent on Local Rod Function in Age-Related Macular Degeneration.

Kumar H, Guymer R, Hodgson L, Hadoux X, Jannaud M, van Wijngaarden P Ophthalmol Sci. 2024; 4(6):100551.

PMID: 39161750 PMC: 11331943. DOI: 10.1016/j.xops.2024.100551.


References
1.
Spaide R, Ooto S, Curcio C . Subretinal drusenoid deposits AKA pseudodrusen. Surv Ophthalmol. 2018; 63(6):782-815. DOI: 10.1016/j.survophthal.2018.05.005. View

2.
Wittenborn J, Clemons T, Regillo C, Rayess N, Liffmann Kruger D, Rein D . Economic Evaluation of a Home-Based Age-Related Macular Degeneration Monitoring System. JAMA Ophthalmol. 2017; 135(5):452-459. PMC: 5470421. DOI: 10.1001/jamaophthalmol.2017.0255. View

3.
Ferris F, Davis M, Clemons T, Lee L, Chew E, Lindblad A . A simplified severity scale for age-related macular degeneration: AREDS Report No. 18. Arch Ophthalmol. 2005; 123(11):1570-4. PMC: 1473206. DOI: 10.1001/archopht.123.11.1570. View

4.
Keenan T, Klein B, Agron E, Chew E, Cukras C, Wong W . CHOROIDAL THICKNESS AND VASCULARITY VARY WITH DISEASE SEVERITY AND SUBRETINAL DRUSENOID DEPOSIT PRESENCE IN NONADVANCED AGE-RELATED MACULAR DEGENERATION. Retina. 2019; 40(4):632-642. PMC: 8327394. DOI: 10.1097/IAE.0000000000002434. View

5.
Domalpally A, Clemons T, Bressler S, Danis R, Elman M, Kim J . Imaging Characteristics of Choroidal Neovascular Lesions in the AREDS2-HOME Study: Report Number 4. Ophthalmol Retina. 2019; 3(4):326-335. DOI: 10.1016/j.oret.2019.01.004. View